FindTrial
Sign In

The study of EPA's effects on coronary plaque inn patients with coronary heart diseases treated with PCI

The study of EPA's effects on coronary plaque inn patients with coronary heart diseases treated with PCI - The effects of EPA on coronary plaque

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000026693
Enrollment
50
Registered
2017-04-01
Start date
2011-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart diseases

Interventions

standard therapy EPA administration

Sponsors

Kurume University Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: patients with stable coronary heart diseases treated with PCI

Exclusion criteria

Exclusion criteria: 1) prior taking EPA, 2) recent acute coronary syndrome (< 1 year), 3) renal insufficiency (serum creatinine > 2.0 mg / dL), 4) hepatic dysfunction (serum AST or ALT > 3-folds of standard value), 5) cancer, 6) autoimmune diseases, 7) impossibility in decision making 8) consideration as inadequate to participating in the study by attending physician.

Design outcomes

Primary

MeasureTime frame
coronary plaque volume—

Secondary

MeasureTime frame
clinical events—

Countries

Japan

Contacts

Public ContactAtsushi Katoh

Kurume University Medical Center Cardiology

katou_atsushi@kurume-u.ac.jp0942-22-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026